The Lancet Gastroenterology & Hepatology in conversation with

Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00145-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00098-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langasContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Adelina Artenie on the incidence of HIV and HCV in people who inject drugs

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article:https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_lancetContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Johan Burisch on the costs of inflammatory bowel disease in high-income settings

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Read the Commission here:The cost of inflammatory bowel disease in high-income settingsContinue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Read the full article:Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE)Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read the full article:Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5)Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Dan Turner on vedolizumab in children with IBD

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Read the full article:Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS)Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv

Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Read the full article:Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT)Continue this conversation on social! Follow us today at... https://bsky.app/profile/lancetgastrohep.bsky.social https://www.linkedin.com/company/langastro/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://youtube.com/thelancettv